Summary
Major players in the glycomics or glycobiology market are Water Corporation, Aligent Technologies, Bruker Corporation, Merck KgaA, New England Biolabs, Danaher Corporation, Shimadzu Corporation, ProZyme Inc., Takara Bio, S-BIO, Asparia Glycomics S.L, Lectenz Bio, Chemily Glycoscience, Z Biotech LLC, and RayBiotech.
The global glycomics or glycobiology market is expected to grow from $1.38 billion in 2022 to $1.60 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The glycomics or glycobiology market is expected to reach $2.82 billion in 2027 at a CAGR of 15.2%.
The glycomics or glycobiology market includes revenues earned by entities by maintaining tissue structure, porosity, and integrity.The market value includes the value of related goods sold by the service provider or included within the service offering.
Only goods and services traded between entities or sold to end consumers are included.
Glycomics or glycobiology refers to the study of the structure, biosynthesis, and biology of saccharides (including sugar chains or glycans) that are widely distributed in nature. Glycans are researched in glycobiology for their structure, production, and biology.
North America was the largest region in the glycomics or glycobiology market in 2022.Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in the glycomics or glycobiology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The major products of glycomics or glycobiology are enzymes, kits, reagents and chemicals, instruments, and carbohydrates.Enzymes refer to biological polymers that catalyze biochemical reactions.
These are used in various applications such as drug discovery and development, disease diagnostics, and others, and these are used in academic research institutes, pharmaceutical, and biotechnology companies and clinical laboratories.
The increase in the demand for medicines for the treatment of several severe chronic diseases is expected to propel the growth of the glycomics or glycobiology market going forward.Chronic diseases are health problems that are usually long-term and can be controlled but not healed.
A glycomics studies changes in glycosylation and its functions, that helps in the development of drugs and related medication for several severe chronic diseases. For instance, in 2022, according to Cancer Facts and Figures 2022-2024, a scientific paper by the American Cancer Society, there would be 22.5 million cancer (a chronic disease) survivors by 2032 and is projected to reach 26 million by 2040. Similarly, Keytruda, a drug used in cancer immunotherapy, became one of the selling drugs in 2020, with revenue accounting for $14.38 billion, an increase of 29.7% compared to 2019. Thus, the increase in the demand for medicines for the treatment of several severe chronic diseases drives the glycomics or glycobiology market.
Investments in research and development activities are a key trend gaining popularity in Glycomics or Glycobiology market.Major research and development institutions are funding in research centers for glycobiology aiming for the research and development of Glycomics or Glycobiology.
For instance, in August 2022, Griffith University, an Australia-based Institute for Glycomics, launched the ACRF International Centre for Cancer Glycomics with a $2.6 million ACRF grant, that is dedicated to achieving cancer glyco-code. This is a unique facility, with a better understanding of the glyco-code that lead to the translation of novel discoveries and clinical outcomes that would help cancer patients improve their lives.
In January 2021, Neogen, a US-based food safety company providing testing solutions for the food industry, acquired Megazyme for an undisclosed amount.Through this acquisition, Neogen gained a Megazyme product line that would help strengthen its business relationships with major food producers and companies.
Megazyme is an Ireland-based developer, and manufacturer of analytical solutions, including glycobiology enzyme products.
The countries covered in the glycomics or glycobiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The glycomics or glycobiology market research report is one of a series of new reports that provides glycomics or glycobiology market statistics, including glycomics or glycobiology industry global market size, regional shares, competitors with a glycomics or glycobiology market share, detailed glycomics or glycobiology market segments, market trends and opportunities, and any further data you may need to thrive in the glycomics or glycobiology industry. This glycomics or glycobiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
